-
1
-
-
42949106166
-
Monoclonal antibodies in cancer therapy: 25 years of progress
-
Oldham R. K., Dillman R. O., Monoclonal antibodies in cancer therapy: 25 years of progress Journal of Clinical Oncology 2008 26 11 1774 1777
-
(2008)
Journal of Clinical Oncology
, vol.26
, Issue.11
, pp. 1774-1777
-
-
Oldham, R.K.1
Dillman, R.O.2
-
2
-
-
0018971622
-
Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen
-
Nadler L. M., Stashenko P., Hardy R., Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen Cancer Research 1980 40 9 3147 3154 (Pubitemid 10043516)
-
(1980)
Cancer Research
, vol.40
, Issue.9
, pp. 3147-3154
-
-
Nadler, L.M.1
Stashenko, P.2
Hardy, R.3
-
3
-
-
0023293149
-
The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine
-
Thistlethwaite J. R. Jr, Haag B. W., Gaber A. O., Stuart J. K., Aronson A. J., Mayes J. T., Lloyd D. M., Stuart F. P., The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine Transplantation Proceedings 1987 19 3 1901 1904
-
(1987)
Transplantation Proceedings
, vol.19
, Issue.3
, pp. 1901-1904
-
-
Thistlethwaite Jr., J.R.1
Haag, B.W.2
Gaber, A.O.3
Stuart, J.K.4
Aronson, A.J.5
Mayes, J.T.6
Lloyd, D.M.7
Stuart, F.P.8
-
4
-
-
73349085919
-
Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer
-
Spector N. L., Blackwell K. L., Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer Journal of Clinical Oncology 2009 27 34 5838 5847
-
(2009)
Journal of Clinical Oncology
, vol.27
, Issue.34
, pp. 5838-5847
-
-
Spector, N.L.1
Blackwell, K.L.2
-
5
-
-
33745738260
-
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic
-
Ranieri G., Patruno R., Ruggieri E., Montemurro S., Valerio P., Ribatti D., Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic Current Medicinal Chemistry 2006 13 16 1845 1857
-
(2006)
Current Medicinal Chemistry
, vol.13
, Issue.16
, pp. 1845-1857
-
-
Ranieri, G.1
Patruno, R.2
Ruggieri, E.3
Montemurro, S.4
Valerio, P.5
Ribatti, D.6
-
6
-
-
77951596808
-
Catumaxomab: Clinical development and future directions
-
Linke R., Klein A., Seimetz D., Catumaxomab: clinical development and future directions mAbs 2010 2 2 129 136
-
(2010)
MAbs
, vol.2
, Issue.2
, pp. 129-136
-
-
Linke, R.1
Klein, A.2
Seimetz, D.3
-
7
-
-
0030923795
-
Vascular endothelial growth factor expression in early stage ovarian carcinoma
-
DOI 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A
-
Paley P. J., Staskus K. A., Gebhard K., Mohanraj D., Twiggs L. B., Carson L. F., Ramakrishnan S., Vascular endothelial growth factor expression in early stage ovarian carcinoma Cancer 1997 80 1 98 106 (Pubitemid 27270925)
-
(1997)
Cancer
, vol.80
, Issue.1
, pp. 98-106
-
-
Paley, P.J.1
Staskus, K.A.2
Gebhard, K.3
Mohanraj, D.4
Twiggs, L.B.5
Carson, L.F.6
Ramakrishnan, S.7
-
8
-
-
1842850792
-
Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients
-
DOI 10.1016/j.clinbiochem.2004.01.014, PII S0009912004000281
-
Kassim S. K., El-Salahy E. M., Fayed S. T., Helal S. A., Helal T., Azzam E. E. D., Khalifa A., Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients Clinical Biochemistry 2004 37 5 363 369 (Pubitemid 38490454)
-
(2004)
Clinical Biochemistry
, vol.37
, Issue.5
, pp. 363-369
-
-
Kassim, S.K.1
El-Salahy, E.M.2
Fayed, S.T.3
Helal, S.A.4
Helal, T.5
Azzam, E.E.-D.6
Khalifa, A.7
-
9
-
-
0036793818
-
Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer
-
Cooper B. C., Ritchie J. M., Broghammer C. L., Coffin J., Sorosky J. I., Buller R. E., Hendrix M. J. C., Sood A. K., Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer Clinical Cancer Research 2002 8 10 3193 3197 (Pubitemid 35155030)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.10
, pp. 3193-3197
-
-
Cooper, B.C.1
Ritchie, J.M.2
Broghammer, C.L.W.3
Coffin, J.4
Sorosky, J.I.5
Buller, R.E.6
Hendrix, M.J.C.7
Sood, A.K.8
-
10
-
-
3242658330
-
Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer
-
Li L., Wang L., Zhang W., Tang B., Zhang J., Song H., Yao D., Tang Y., Chen X., Yang Z., Wang G., Li X., Zhao J., Ding H., Reed E., Li Q. Q., Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer Anticancer Research 2004 24 3 1973 1979 (Pubitemid 38954620)
-
(2004)
Anticancer Research
, vol.24
, Issue.B3
, pp. 1973-1979
-
-
Li, L.1
Wang, L.2
Zhang, W.3
Tang, B.4
Zhang, J.5
Song, H.6
Yao, D.7
Tang, Y.8
Chen, X.9
Yang, Z.10
Wang, G.11
Li, X.12
Zhao, J.13
Ding, H.14
Reed, E.15
Li, Q.Q.16
-
11
-
-
33751006991
-
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer
-
DOI 10.1016/j.ygyno.2006.03.058, PII S0090825806002903
-
Hefler L. A., Zeillinger R., Grimm C., Sood A. K., Cheng W. F., Gadducci A., Tempfer C. B., Reinthaller A., Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer Gynecologic Oncology 2006 103 2 512 517 (Pubitemid 44740099)
-
(2006)
Gynecologic Oncology
, vol.103
, Issue.2
, pp. 512-517
-
-
Hefler, L.A.1
Zeillinger, R.2
Grimm, C.3
Sood, A.K.4
Cheng, W.F.5
Gadducci, A.6
Tempfer, C.B.7
Reinthaller, A.8
-
12
-
-
61449097778
-
Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer
-
Kuemmel S., Thomas A., Landt S., Fuger A., Schmid P., Kriner M., Blohmer J. U., Sehouli J., Schaller G., Lichtenegger W., Kninger A., Fuchs I., Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer Anticancer Research 2009 29 2 641 645
-
(2009)
Anticancer Research
, vol.29
, Issue.2
, pp. 641-645
-
-
Kuemmel, S.1
Thomas, A.2
Landt, S.3
Fuger, A.4
Schmid, P.5
Kriner, M.6
Blohmer, J.U.7
Sehouli, J.8
Schaller, G.9
Lichtenegger, W.10
Kninger, A.11
Fuchs, I.12
-
13
-
-
60449083456
-
Markers of angiogenesis in high-risk, early-stage cervical cancer: A gynecologic oncology group study
-
Randall L. M., Monk B. J., Darcy K. M., Tian C., Burger R. A., Liao S. Y., Peters W. A., Stock R. J., Fruehauf J. P., Markers of angiogenesis in high-risk, early-stage cervical cancer: a gynecologic oncology group study Gynecologic Oncology 2009 112 3 583 589
-
(2009)
Gynecologic Oncology
, vol.112
, Issue.3
, pp. 583-589
-
-
Randall, L.M.1
Monk, B.J.2
Darcy, K.M.3
Tian, C.4
Burger, R.A.5
Liao, S.Y.6
Peters, W.A.7
Stock, R.J.8
Fruehauf, J.P.9
-
14
-
-
0034796595
-
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
-
DOI 10.1038/nm0901-987
-
Jain R. K., Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nature Medicine 2001 7 9 987 989 (Pubitemid 32937367)
-
(2001)
Nature Medicine
, vol.7
, Issue.9
, pp. 987-989
-
-
Jain, R.K.1
-
15
-
-
11844254414
-
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
-
DOI 10.1126/science.1104819
-
Jain R. K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 2005 307 5706 58 62 (Pubitemid 40093472)
-
(2005)
Science
, vol.307
, Issue.5706
, pp. 58-62
-
-
Jain, R.K.1
-
16
-
-
79957902010
-
Signal transduction by vascular endothelial growth factor receptors
-
Koch S., Tugues S., Li X., Signal transduction by vascular endothelial growth factor receptors Biochemical Journal 2011 437 2 169 183
-
(2011)
Biochemical Journal
, vol.437
, Issue.2
, pp. 169-183
-
-
Koch, S.1
Tugues, S.2
Li, X.3
-
17
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E. A., Shenkier T., Cella D., Davidson N. E., Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer New England Journal of Medicine 2007 357 26 2666 2676
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.26
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
Dickler, M.4
Cobleigh, M.5
Perez, E.A.6
Shenkier, T.7
Cella, D.8
Davidson, N.E.9
-
18
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer New England Journal of Medicine 2004 350 23 2335 2342 (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
19
-
-
62449124416
-
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL
-
Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., Leighl N., Mezger J., Archer V., Moore N., Manegold C., Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL Journal of Clinical Oncology 2009 27 8 1227 1234
-
(2009)
Journal of Clinical Oncology
, vol.27
, Issue.8
, pp. 1227-1234
-
-
Reck, M.1
Von Pawel, J.2
Zatloukal, P.3
Ramlau, R.4
Gorbounova, V.5
Hirsh, V.6
Leighl, N.7
Mezger, J.8
Archer, V.9
Moore, N.10
Manegold, C.11
-
21
-
-
13844266766
-
Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer
-
DOI 10.1016/j.ygyno.2004.12.001
-
Monk B. J., Choi D. C., Pugmire G., Burger R. A., Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer Gynecologic Oncology 2005 96 3 902 905 (Pubitemid 40255525)
-
(2005)
Gynecologic Oncology
, vol.96
, Issue.3
, pp. 902-905
-
-
Monk, B.J.1
Choi, D.C.2
Pugmire, G.3
Burger, R.A.4
-
22
-
-
33745308428
-
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis
-
DOI 10.1002/cncr.21969
-
Wright J. D., Hagemann A., Rader J. S., Viviano D., Gibb R. K., Norris L., Mutch D. G., Powell M. A., Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis Cancer 2006 107 1 83 89 (Pubitemid 43939034)
-
(2006)
Cancer
, vol.107
, Issue.1
, pp. 83-89
-
-
Wright, J.D.1
Hagemann, A.2
Rader, J.S.3
Viviano, D.4
Gibb, R.K.5
Norris, L.6
Mutch, D.G.7
Powell, M.A.8
-
23
-
-
33745875210
-
Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer
-
DOI 10.1016/j.ygyno.2006.01.030, PII S009082580600059X
-
Cohn D. E., Valmadre S., Resnick K. E., Eaton L. A., Copeland L. J., Fowler J. M., Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer Gynecologic Oncology 2006 102 2 134 139 (Pubitemid 44056263)
-
(2006)
Gynecologic Oncology
, vol.102
, Issue.2
, pp. 134-139
-
-
Cohn, D.E.1
Valmadre, S.2
Resnick, K.E.3
Eaton, L.A.4
Copeland, L.J.5
Fowler, J.M.6
-
24
-
-
36849019301
-
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A gynecologic oncology group study
-
Burger R. A., Sill M. W., Monk B. J., Greer B. E., Sorosky J. I., Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study Journal of Clinical Oncology 2007 25 33 5165 5167
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.33
, pp. 5165-5167
-
-
Burger, R.A.1
Sill, M.W.2
Monk, B.J.3
Greer, B.E.4
Sorosky, J.I.5
-
25
-
-
35348904080
-
Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
-
DOI 10.1016/j.ygyno.2007.07.017, PII S0090825807004635
-
Chura J. C., van Iseghem K., Downs L. S. Jr, Carson L. F., Judson P. L., Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer Gynecologic Oncology 2007 107 2 326 330 (Pubitemid 47575735)
-
(2007)
Gynecologic Oncology
, vol.107
, Issue.2
, pp. 326-330
-
-
Chura, J.C.1
Van Iseghem, K.2
Downs Jr., L.S.3
Carson, L.F.4
Judson, P.L.5
-
26
-
-
34648829056
-
Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening
-
DOI 10.1016/j.ygyno.2007.06.004, PII S0090825807004179
-
Simpkins F., Belinson J. L., Rose P. G., Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening Gynecologic Oncology 2007 107 1 118 123 (Pubitemid 47464553)
-
(2007)
Gynecologic Oncology
, vol.107
, Issue.1
, pp. 118-123
-
-
Simpkins, F.1
Belinson, J.L.2
Rose, P.G.3
-
27
-
-
37849035249
-
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret hospital phase II consortia
-
Garcia A. A., Hirte H., Fleming G., Yang D., Tsao-Wei D. D., Roman L., Groshen S., Swenson S., Markland F., Gandara D., Scudder S., Morgan R., Chen H., Lenz H. J., Oza A. M., Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret hospital phase II consortia Journal of Clinical Oncology 2008 26 1 76 82
-
(2008)
Journal of Clinical Oncology
, vol.26
, Issue.1
, pp. 76-82
-
-
Garcia, A.A.1
Hirte, H.2
Fleming, G.3
Yang, D.4
Tsao-Wei, D.D.5
Roman, L.6
Groshen, S.7
Swenson, S.8
Markland, F.9
Gandara, D.10
Scudder, S.11
Morgan, R.12
Chen, H.13
Lenz, H.J.14
Oza, A.M.15
-
28
-
-
49249113484
-
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
-
Azad N. S., Posadas E. M., Kwitkowski V. E., Steinberg S. M., Jain L., Annunziata C. M., Minasian L., Sarosy G., Kotz H. L., Premkumar A., Cao L., McNally D., Chow C., Chen H. X., Wright J. J., Figg W. D., Kohn E. C., Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity Journal of Clinical Oncology 2008 26 22 3709 3714
-
(2008)
Journal of Clinical Oncology
, vol.26
, Issue.22
, pp. 3709-3714
-
-
Azad, N.S.1
Posadas, E.M.2
Kwitkowski, V.E.3
Steinberg, S.M.4
Jain, L.5
Annunziata, C.M.6
Minasian, L.7
Sarosy, G.8
Kotz, H.L.9
Premkumar, A.10
Cao, L.11
McNally, D.12
Chow, C.13
Chen, H.X.14
Wright, J.J.15
Figg, W.D.16
Kohn, E.C.17
-
29
-
-
45549099056
-
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
-
Nimeiri H. S., Oza A. M., Morgan R. J., Friberg G., Kasza K., Faoro L., Salgia R., Stadler W. M., Vokes E. E., Fleming G. F., Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II consortia Gynecologic Oncology 2008 110 1 49 55
-
(2008)
Gynecologic Oncology
, vol.110
, Issue.1
, pp. 49-55
-
-
Nimeiri, H.S.1
Oza, A.M.2
Morgan, R.J.3
Friberg, G.4
Kasza, K.5
Faoro, L.6
Salgia, R.7
Stadler, W.M.8
Vokes, E.E.9
Fleming, G.F.10
-
30
-
-
70350566692
-
Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer
-
Hurt J. D., Richardson D. L., Seamon L. G., Fowler J. F., Copeland L. J., Cohn D. E., Eisenhauer E., Salani R., O'Malley D. M., Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer Gynecologic Oncology 2009 115 3 396 400
-
(2009)
Gynecologic Oncology
, vol.115
, Issue.3
, pp. 396-400
-
-
Hurt, J.D.1
Richardson, D.L.2
Seamon, L.G.3
Fowler, J.F.4
Copeland, L.J.5
Cohn, D.E.6
Eisenhauer, E.7
Salani, R.8
O'Malley, D.M.9
-
31
-
-
33748475636
-
The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma
-
DOI 10.1016/j.ygyno.2006.05.018, PII S0090825806004306
-
Numnum T. M., Rocconi R. P., Whitworth J., Barnes M. N., The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma Gynecologic Oncology 2006 102 3 425 428 (Pubitemid 44353660)
-
(2006)
Gynecologic Oncology
, vol.102
, Issue.3
, pp. 425-428
-
-
Numnum, T.M.1
Rocconi, R.P.2
Whitworth, J.3
Barnes, M.N.4
-
32
-
-
40549084381
-
Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma
-
DOI 10.1111/j.1525-1438.2007.01026.x
-
Arora N., Tewari D., Cowan C., Saffari B., Monk B. J., Burger R. A., Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma International Journal of Gynecological Cancer 2008 18 2 369 372 (Pubitemid 351365222)
-
(2008)
International Journal of Gynecological Cancer
, vol.18
, Issue.2
, pp. 369-372
-
-
Arora, N.1
Tewari, D.2
Cowan, C.3
Saffari, B.4
Monk, B.J.5
Burger, R.A.6
-
33
-
-
56449083663
-
Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer
-
Hamilton C. A., Maxwell G. L., Chernofsky M. R., Bernstein S. A., Farley J. H., Rose G. S., Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer Gynecologic Oncology 2008 111 3 530 532
-
(2008)
Gynecologic Oncology
, vol.111
, Issue.3
, pp. 530-532
-
-
Hamilton, C.A.1
Maxwell, G.L.2
Chernofsky, M.R.3
Bernstein, S.A.4
Farley, J.H.5
Rose, G.S.6
-
34
-
-
56449083159
-
The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: A case report
-
Kesterson J. P., Mhawech-Fauceglia P., Lele S., The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report Gynecologic Oncology 2008 111 3 527 529
-
(2008)
Gynecologic Oncology
, vol.111
, Issue.3
, pp. 527-529
-
-
Kesterson, J.P.1
Mhawech-Fauceglia, P.2
Lele, S.3
-
35
-
-
78549259164
-
Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review
-
Bellati F., Napoletano C., Ruscito I., Pastore M., Pernice M., Antonilli M., Nuti M., Benedetti Panici P., Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review Investigational New Drugs 2010 28 6 887 894
-
(2010)
Investigational New Drugs
, vol.28
, Issue.6
, pp. 887-894
-
-
Bellati, F.1
Napoletano, C.2
Ruscito, I.3
Pastore, M.4
Pernice, M.5
Antonilli, M.6
Nuti, M.7
Benedetti Panici, P.8
-
36
-
-
78650060554
-
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression
-
Napoletano C., Bellati F., Landi R., Pauselli S., Marchetti C., Visconti V., Sale P., Liberati M., Rughetti A., Frati L., Panici P. B., Nuti M., Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression Journal of Cellular and Molecular Medicine 2010 14 12 2748 2759
-
(2010)
Journal of Cellular and Molecular Medicine
, vol.14
, Issue.12
, pp. 2748-2759
-
-
Napoletano, C.1
Bellati, F.2
Landi, R.3
Pauselli, S.4
Marchetti, C.5
Visconti, V.6
Sale, P.7
Liberati, M.8
Rughetti, A.9
Frati, L.10
Panici, P.B.11
Nuti, M.12
-
37
-
-
84855605968
-
-
ID protocol number: NCT00262847
-
http://www.cancer.gov/ (ID protocol number: NCT00262847)
-
-
-
-
38
-
-
84855600478
-
-
(ID protocol number: NCT00483782)
-
http://www.cancer.gov/ (ID protocol number: NCT00483782)
-
-
-
-
39
-
-
84855600479
-
-
(ID protocol number: NCT00976911)
-
http://www.cancer.gov/ (ID protocol number: NCT00976911)
-
-
-
-
40
-
-
84855578023
-
-
(ID protocol number: NCT00565851)
-
http://www.cancer.gov/ (ID protocol number: NCT00565851)
-
-
-
-
41
-
-
84855600477
-
-
(ID protocol number: NCT00434642)
-
http://www.cancer.gov (ID protocol number: NCT00434642)
-
-
-
-
42
-
-
0041629450
-
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
-
DOI 10.1200/JCO.2003.01.504
-
Mendelsohn J., Baselga J., Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer Journal of Clinical Oncology 2003 21 14 2787 2799 (Pubitemid 46606324)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.14
, pp. 2787-2799
-
-
Mendelsohn, J.1
Baselga, J.2
-
43
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon D. J., Clark G. M., Wong S. G., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987 235 4785 177 182 (Pubitemid 17231334)
-
(1987)
Science
, vol.235
, Issue.4785
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
44
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A., Press M. F., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 1989 244 4905 707 712 (Pubitemid 19147683)
-
(1989)
Science
, vol.244
, Issue.4905
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
Holt, J.A.4
Wong, S.G.5
Keith, D.E.6
Levin, W.J.7
Stuart, S.G.8
Udove, J.9
Ullrich, A.10
Press, M.F.11
-
45
-
-
28444443755
-
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma
-
DOI 10.1093/annonc/mdi405
-
Delord J. P., Allal C., Canal M., Mery E., Rochaix P., Hennebelle I., Pradines A., Chatelut E., Bugat R., Guichard S., Canal P., Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma Annals of Oncology 2005 16 12 1889 1897 (Pubitemid 41724277)
-
(2005)
Annals of Oncology
, vol.16
, Issue.12
, pp. 1889-1897
-
-
Delord, J.P.1
Allal, C.2
Canal, M.3
Mery, E.4
Rochaix, P.5
Hennebelle, I.6
Pradines, A.7
Chatelut, E.8
Bugat, R.9
Guichard, S.10
Canal, P.11
-
46
-
-
0036869728
-
HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: Possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab
-
Fujimura M., Katsumata N., Tsuda H., Uchi N., Miyazaki S., Hidaka T., Sakai M., Saito S., HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab Japanese Journal of Cancer Research 2002 93 11 1250 1257 (Pubitemid 36032989)
-
(2002)
Japanese Journal of Cancer Research
, vol.93
, Issue.11
, pp. 1250-1257
-
-
Fujimura, M.1
Katsumata, N.2
Tsuda, H.3
Uchi, N.4
Miyazaki, S.5
Hidaka, T.6
Sakai, M.7
Saito, S.8
-
48
-
-
77955301982
-
Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy
-
Bellati F., Napoletano C., Ruscito I., Liberati M., Panici P. B., Nuti M., Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy Journal of Clinical Oncology 2010 28 21 e369 e370
-
(2010)
Journal of Clinical Oncology
, vol.28
, Issue.21
-
-
Bellati, F.1
Napoletano, C.2
Ruscito, I.3
Liberati, M.4
Panici, P.B.5
Nuti, M.6
-
50
-
-
0037440042
-
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
-
DOI 10.1200/JCO.2003.10.104
-
Bookman M. A., Darcy K. M., Clarke-Pearson D., Boothby R. A., Horowitz I. R., Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group Journal of Clinical Oncology 2003 21 2 283 290 (Pubitemid 46606157)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.2
, pp. 283-290
-
-
Bookman, M.A.1
Darcy, K.M.2
Clarke-Pearson, D.3
Boothby, R.A.4
Horowitz, I.R.5
-
51
-
-
1842605531
-
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
-
DOI 10.1016/S1535-6108(04)00083-2, PII S1535610804000832
-
Franklin M. C., Carey K. D., Vajdos F. F., Leahy D. J., de Vos A. M., Sliwkowski M. X., Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex Cancer Cell 2004 5 4 317 328 (Pubitemid 38482068)
-
(2004)
Cancer Cell
, vol.5
, Issue.4
, pp. 317-328
-
-
Franklin, M.C.1
Carey, K.D.2
Vajdos, F.F.3
Leahy, D.J.4
De Vos, A.M.5
Sliwkowski, M.X.6
-
52
-
-
0035874981
-
Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells
-
Molina M. A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J., Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells Cancer Research 2001 61 12 4744 4749 (Pubitemid 32691885)
-
(2001)
Cancer Research
, vol.61
, Issue.12
, pp. 4744-4749
-
-
Molina, M.A.1
Codony-Servat, J.2
Albanell, J.3
Rojo, F.4
Arribas, J.5
Baselga, J.6
-
53
-
-
33749003463
-
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status
-
DOI 10.1200/JCO.2005.05.4221
-
Gordon M. S., Matei D., Aghajanian C. J., Matulonis U. A., Brewer M., Fleming G. F., Hainsworth J. D., Garcia A. A., Pegram M. D., Schilder R. J., Cohn D. E., Roman L., Derynck M. K., Ng K., Lyons B., Allison D. E., Eberhard D. A., Pham T. Q., Dere R. C., Karlan B. Y., Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status Journal of Clinical Oncology 2006 24 26 4324 4332 (Pubitemid 46630791)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.26
, pp. 4324-4332
-
-
Gordon, M.S.1
Matei, D.2
Aghajanian, C.3
Matulonis, U.A.4
Brewer, M.5
Fleming, G.F.6
Hainsworth, J.D.7
Garcia, A.A.8
Pegram, M.D.9
Schilder, R.J.10
Cohn, D.E.11
Roman, L.12
Derynck, M.K.13
Ng, K.14
Lyons, B.15
Allison, D.E.16
Eberhard, D.A.17
Pham, T.Q.18
Dere, R.C.19
Karlan, B.Y.20
more..
-
54
-
-
77949900758
-
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
-
Makhija S., Amler L. C., Glenn D., Ueland F. R., Gold M. A., Dizon D. S., Paton V., Lin C. Y., Januario T., Ng K., Strauss A., Kelsey S., Sliwkowski M. X., Matulonis U., Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer Journal of Clinical Oncology 2010 28 7 1215 1223
-
(2010)
Journal of Clinical Oncology
, vol.28
, Issue.7
, pp. 1215-1223
-
-
Makhija, S.1
Amler, L.C.2
Glenn, D.3
Ueland, F.R.4
Gold, M.A.5
Dizon, D.S.6
Paton, V.7
Lin, C.Y.8
Januario, T.9
Ng, K.10
Strauss, A.11
Kelsey, S.12
Sliwkowski, M.X.13
Matulonis, U.14
-
55
-
-
0030054907
-
Anti-tremor and cell cycle responses in KB celIs treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin
-
Prewett M., Rockwell P., Rose C., Goldstein N. I., Anti-tremor and cell cycle responses in KB celIs treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin International Journal of Oncology 1996 9 2 217 224 (Pubitemid 26236011)
-
(1996)
International Journal of Oncology
, vol.9
, Issue.2
, pp. 217-224
-
-
Prewett, M.1
Rockwell, P.2
Rose, C.3
Goldstein, N.I.4
-
56
-
-
39249085402
-
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A gynecologic oncology group study
-
Secord A. A., Blessing J. A., Armstrong D. K., Rodgers W. H., Miner Z., Barnes M. N., Lewandowski G., Mannel R. S., Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a gynecologic oncology group study Gynecologic Oncology 2008 108 493 499
-
(2008)
Gynecologic Oncology
, vol.108
, pp. 493-499
-
-
Secord, A.A.1
Blessing, J.A.2
Armstrong, D.K.3
Rodgers, W.H.4
Miner, Z.5
Barnes, M.N.6
Lewandowski, G.7
Mannel, R.S.8
-
57
-
-
0027428571
-
Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
-
Fan Z., Baselga J., Masui H., Mendelsohn J., Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts Cancer Research 1993 53 19 4637 4642 (Pubitemid 23304392)
-
(1993)
Cancer Research
, vol.53
, Issue.18
, pp. 4637-4642
-
-
Fan, Z.1
Baselga, J.2
Masui, H.3
Mendelsohn, J.4
-
58
-
-
0028819660
-
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
-
Goldstein N. I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J., Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clinical Cancer Research 1995 1 11 1311 1318
-
(1995)
Clinical Cancer Research
, vol.1
, Issue.11
, pp. 1311-1318
-
-
Goldstein, N.I.1
Prewett, M.2
Zuklys, K.3
Rockwell, P.4
Mendelsohn, J.5
-
59
-
-
16244371388
-
Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells
-
New Anticancer Agents
-
Sung F. L., Poon T. C., Hui E. P., Ma B. B. Y., Liong E., To K. F., Huang D. P. W. S., Chan A. T. C., Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells In Vivo 2005 19 1 237 246 (Pubitemid 40450402)
-
(2005)
Vivo
, vol.19
, Issue.1
, pp. 237-246
-
-
Sung, F.L.1
Poon, T.C.W.2
Hui, E.P.3
Ma, B.B.Y.4
Liong, E.5
To, K.F.6
Huang, D.P.W.S.7
Chan, A.T.C.8
-
60
-
-
33645749886
-
In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR
-
Balin-Gauthier D., Delord J. P., Rochaix P., Mallard V., Thomas F., Hennebelle I., Bugat R., Canal P., Allal C., In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR Cancer Chemotherapy and Pharmacology 2006 57 6 709 718
-
(2006)
Cancer Chemotherapy and Pharmacology
, vol.57
, Issue.6
, pp. 709-718
-
-
Balin-Gauthier, D.1
Delord, J.P.2
Rochaix, P.3
Mallard, V.4
Thomas, F.5
Hennebelle, I.6
Bugat, R.7
Canal, P.8
Allal, C.9
-
61
-
-
47249145102
-
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
-
Konner J., Schilder R. J., DeRosa F. A., Gerst S. R., Tew W. P., Sabbatini P. J., Hensley M. L., Spriggs D. R., Aghajanian C. A., A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer Gynecologic Oncology 2008 110 2 140 145
-
(2008)
Gynecologic Oncology
, vol.110
, Issue.2
, pp. 140-145
-
-
Konner, J.1
Schilder, R.J.2
Derosa, F.A.3
Gerst, S.R.4
Tew, W.P.5
Sabbatini, P.J.6
Hensley, M.L.7
Spriggs, D.R.8
Aghajanian, C.A.9
-
62
-
-
70349745159
-
A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: A gynecologic oncology group study
-
Fiorica J. V., Blessing J. A., Puneky L. V., Secord A. A., Hoffman J. S., Yamada S. D., Buekers T. E., Bell J., Schilder J. M., A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a gynecologic oncology group study Gynecologic Oncology 2009 115 2 285 289
-
(2009)
Gynecologic Oncology
, vol.115
, Issue.2
, pp. 285-289
-
-
Fiorica, J.V.1
Blessing, J.A.2
Puneky, L.V.3
Secord, A.A.4
Hoffman, J.S.5
Yamada, S.D.6
Buekers, T.E.7
Bell, J.8
Schilder, J.M.9
-
63
-
-
34447132202
-
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I/II study
-
DOI 10.1158/1078-0432.CCR-06-2769
-
Burges A., Wimberger P., Kmper C., Gorbounova V., Sommer H., Schmalfeldt B., Pfisterer J., Lichinitser M., Makhson A., Moiseyenko V., Lahr A., Schulze E., Jger M., Strhlein M. A., Heiss M. M., Gottwald T., Lindhofer H., Kimmig R., Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study Clinical Cancer Research 2007 13 13 3899 3905 (Pubitemid 47037597)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.13
, pp. 3899-3905
-
-
Burges, A.1
Wimberger, P.2
Kumper, C.3
Gorbounova, V.4
Sommer, H.5
Schmalfeldt, B.6
Pfisterer, J.7
Lichinitser, M.8
Makhson, A.9
Moiseyenko, V.10
Lahr, A.11
Schulze, E.12
Jager, M.13
Strohlein, M.A.14
Heiss, M.M.15
Gottwald, T.16
Lindhofer, H.17
Kimmig, R.18
-
64
-
-
0034051390
-
The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells
-
Zeidler R., Mysliwietz J., Csnady M., Walz A., Ziegler I., Schmitt B., Wollenberg B., Lindhofer H., The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells British Journal of Cancer 2000 83 2 261 266 (Pubitemid 30411727)
-
(2000)
British Journal of Cancer
, vol.83
, Issue.2
, pp. 261-266
-
-
Zeidler, R.1
Mysliwietz, J.2
Csanady, M.3
Walz, A.4
Ziegler, I.5
Schmitt, B.6
Wollenberg, B.7
Lindhofer, H.8
-
65
-
-
26444592251
-
Immunotherapy of malignant ascites with trifunctional antibodies
-
DOI 10.1002/ijc.21165
-
Heiss M. M., Strhlein M. A., Jger M., Kimmig R., Burges A., Schoberth A., Jauch K. W., Schildberg F. W., Lindhofer H., Immunotherapy of malignant ascites with trifunctional antibodies International Journal of Cancer 2005 117 3 435 443 (Pubitemid 41429567)
-
(2005)
International Journal of Cancer
, vol.117
, Issue.3
, pp. 435-443
-
-
Heiss, M.M.1
Strohlein, M.A.2
Jager, M.3
Kimmig, R.4
Burges, A.5
Schoberth, A.6
Jauch, K.-W.7
Schildberg, F.-W.8
Lindhofer, H.9
-
66
-
-
77954676136
-
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
-
Heiss M. M., Murawa P., Koralewski P., Kutarska E., Kolesnik O. O., Ivanchenko V. V., Dudnichenko A. S., Aleknaviciene B., Razbadauskas A., Gore M., Ganea-Motan E., Ciuleanu T., Wimberger P., Schmittel A., Schmalfeldt B., Burges A., Bokemeyer C., Lindhofer H., Lahr A., Parsons S. L., The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial International Journal of Cancer 2010 127 9 2209 2221
-
(2010)
International Journal of Cancer
, vol.127
, Issue.9
, pp. 2209-2221
-
-
Heiss, M.M.1
Murawa, P.2
Koralewski, P.3
Kutarska, E.4
Kolesnik, O.O.5
Ivanchenko, V.V.6
Dudnichenko, A.S.7
Aleknaviciene, B.8
Razbadauskas, A.9
Gore, M.10
Ganea-Motan, E.11
Ciuleanu, T.12
Wimberger, P.13
Schmittel, A.14
Schmalfeldt, B.15
Burges, A.16
Bokemeyer, C.17
Lindhofer, H.18
Lahr, A.19
Parsons, S.L.20
more..
-
67
-
-
80052593787
-
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO study group
-
Baumann K., Pfisterer J., Wimberger P., Burchardi N., Kurzeder C., du Bois A., Loibl S., Sehouli J., Huober J., Schmalfeldt B., Vergote I., Lck H. J., Wagner U., Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO study group Gynecologic Oncology 2011 123 1 27 32
-
(2011)
Gynecologic Oncology
, vol.123
, Issue.1
, pp. 27-32
-
-
Baumann, K.1
Pfisterer, J.2
Wimberger, P.3
Burchardi, N.4
Kurzeder, C.5
Du Bois, A.6
Loibl, S.7
Sehouli, J.8
Huober, J.9
Schmalfeldt, B.10
Vergote, I.11
Lck, H.J.12
Wagner, U.13
-
68
-
-
36849091953
-
MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer
-
Kalli K. R., MORAb-003, a fully humanized monoclonal antibody against the folate receptor, for the potential treatment of epithelial ovarian cancer Current Opinion in Investigational Drugs 2007 8 12 1067 1073 (Pubitemid 350224332)
-
(2007)
Current Opinion in Investigational Drugs
, vol.8
, Issue.12
, pp. 1067-1073
-
-
Kalli, K.R.1
-
69
-
-
40749130870
-
Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003
-
DOI 10.1016/j.nucmedbio.2007.12.008, PII S0969805108000061
-
Smith-Jones P. M., Pandit-Taskar N., Cao W., O'Donoghue J., Philips M. D., Carrasquillo J., Konner J. A., Old L. J., Larson S. M., Preclinical radioimmunotargeting of folate receptor using the monoclonal antibody conjugate DOTA-MORAb-003 Nuclear Medicine and Biology 2008 35 3 343 351 (Pubitemid 351381971)
-
(2008)
Nuclear Medicine and Biology
, vol.35
, Issue.3
, pp. 343-351
-
-
Smith-Jones, P.M.1
Pandit-Taskar, N.2
Cao, W.3
O'Donoghue, J.4
Philips, M.D.5
Carrasquillo, J.6
Konner, J.A.7
Old, L.J.8
Larson, S.M.9
-
71
-
-
0020559574
-
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
-
Bast R. C. Jr, Klug T. L., St John E., A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer New England Journal of Medicine 1983 309 15 883 887 (Pubitemid 13014028)
-
(1983)
New England Journal of Medicine
, vol.309
, Issue.15
, pp. 883-887
-
-
Bast Jr., R.C.1
Klug, T.L.2
St. John, E.3
-
72
-
-
33644843331
-
Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide
-
DOI 10.1200/JCO.2005.01.2757
-
Rustin G. J., Timmers P., Nelstrop A., Shreeves G., Bentzen S. M., Baron B., Piccart M. J., Bertelsen K., Stuart G., Cassidy J., Eisenhauer E., Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide Journal of Clinical Oncology 2006 24 1 45 51 (Pubitemid 46630492)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.1
, pp. 45-51
-
-
Rustin, G.J.S.1
Timmers, P.2
Nelstrop, A.3
Shreeves, G.4
Bentzen, S.M.5
Baron, B.6
Piccart, M.J.7
Bertelsen, K.8
Stuart, G.9
Cassidy, J.10
Eisenhauer, E.11
-
73
-
-
0035886979
-
Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels
-
Rustin G. J., Marples M., Nelstrop A. E., Mahmoudi M., Meyer T., Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels Journal of Clinical Oncology 2001 19 20 4054 4057 (Pubitemid 32976692)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.20
, pp. 4054-4057
-
-
Rustin, G.J.S.1
Marples, M.2
Nelstrop, A.E.3
Mahmoudi, M.4
Meyer, T.5
-
74
-
-
0038336598
-
Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer
-
DOI 10.1067/mob.2003.347
-
Mbus V. J., Baum R. P., Bolle M., Kreienberg R., Noujaim A. A., Schultes B. C., Nicodemus C. F., Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer American Journal of Obstetrics and Gynecology 2003 189 1 28 36 (Pubitemid 36886520)
-
(2003)
American Journal of Obstetrics and Gynecology
, vol.189
, Issue.1
, pp. 28-36
-
-
Mobus, V.J.1
Baum, R.P.2
Bolle, M.3
Kreienberg, R.4
Noujaim, A.A.5
Schultes, B.C.6
Nicodemus, C.F.7
-
75
-
-
0027823738
-
Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13
-
Baum R. P., Noujaim A. A., Nanci A., Moebus V., Hertel A., Niesen A., Donnerstag B., Sykes T., Boniface G., Hor G., Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13 Hybridoma 1993 12 5 583 589 (Pubitemid 24198149)
-
(1993)
Hybridoma
, vol.12
, Issue.5
, pp. 583-589
-
-
Baum, R.P.1
Noujaim, A.A.2
Nanci, A.3
Moebus, V.4
Hertel, A.5
Niesen, A.6
Donnerstag, B.7
Sykes, T.8
Boniface, G.9
Hor, G.10
-
76
-
-
0031747870
-
1)
-
DOI 10.1007/s002620050479
-
Schultes B. C., Baum R. P., Niesen A., Noujaim A. A., Madiyalakan R., Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1) Cancer Immunology Immunotherapy 1998 46 4 201 212 (Pubitemid 28293820)
-
(1998)
Cancer Immunology Immunotherapy
, vol.46
, Issue.4
, pp. 201-212
-
-
Schultes, B.C.1
Baum, R.P.2
Niesen, A.3
Noujaim, A.A.4
Madiyalakan, R.5
-
77
-
-
0034947607
-
Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13 - Evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo
-
Noujaim A. A., Schultes B. C., Baum R. P., Madiyalakan R., Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo Cancer Biotherapy and Radiopharmaceuticals 2001 16 3 187 203 (Pubitemid 32641217)
-
(2001)
Cancer Biotherapy and Radiopharmaceuticals
, vol.16
, Issue.3
, pp. 187-203
-
-
Noujaim, A.A.1
Schultes, B.C.2
Baum, R.P.3
Madiyalakan, R.4
-
78
-
-
3142670929
-
CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients
-
DOI 10.1016/j.ygyno.2004.04.024, PII S0090825804002781
-
Gordon A. N., Schultes B. C., Gallion H., Edwards R., Whiteside T. L., Cermak J. M., Nicodemus C. F., CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients Gynecologic Oncology 2004 94 2 340 351 (Pubitemid 39024536)
-
(2004)
Gynecologic Oncology
, vol.94
, Issue.2
, pp. 340-351
-
-
Gordon, A.N.1
Schultes, B.C.2
Gallion, H.3
Edwards, R.4
Whiteside, T.L.5
Cermak, J.M.6
Nicodemus, C.F.7
-
79
-
-
4444383336
-
Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer
-
DOI 10.1200/JCO.2004.09.016
-
Berek J. S., Taylor P. T., Gordon A., Cunningham M. J., Finkler N., Orr J., Rivkin S., Schultes B. C., Whiteside T. L., Nicodemus C. F., Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer Journal of Clinical Oncology 2004 22 17 3507 3516 (Pubitemid 41103657)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.17
, pp. 3507-3516
-
-
Berek, J.S.1
Taylor, P.T.2
Gordon, A.3
Cunningham, M.J.4
Finkler, N.5
Orr Jr., J.6
Rivkin, S.7
Schultes, B.C.8
Whiteside, T.L.9
Nicodemus, C.F.10
-
80
-
-
14244250598
-
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer
-
DOI 10.1111/j.1525-1438.2005.00483.x
-
Ehlen T. G., Hoskins P. J., Miller D., Whiteside T. L., Nicodemus C. F., Schultes B. C., Swenerton K. D., A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer International Journal of Gynecological Cancer 2005 15 6 1023 1034 (Pubitemid 43110150)
-
(2005)
International Journal of Gynecological Cancer
, vol.15
, Issue.6
, pp. 1023-1034
-
-
Ehlen, T.G.1
Hoskins, P.J.2
Miller, D.3
Whiteside, T.L.4
Nicodemus, C.F.5
Schultes, B.C.6
Swenerton, K.D.7
-
81
-
-
44949115169
-
CA125 velocity at relapse is a highly significant predictor of survival post relapse: Results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer
-
Berek J. S., Taylor P. T., Nicodemus C. F., CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer Journal of Immunotherapy 2008 31 2 207 214
-
(2008)
Journal of Immunotherapy
, vol.31
, Issue.2
, pp. 207-214
-
-
Berek, J.S.1
Taylor, P.T.2
Nicodemus, C.F.3
-
82
-
-
58549088720
-
Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer
-
Berek J., Taylor P., McGuire W., Smith L. M., Schultes B., Nicodemus C. F., Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer Journal of Clinical Oncology 2009 27 3 418 425
-
(2009)
Journal of Clinical Oncology
, vol.27
, Issue.3
, pp. 418-425
-
-
Berek, J.1
Taylor, P.2
McGuire, W.3
Smith, L.M.4
Schultes, B.5
Nicodemus, C.F.6
-
83
-
-
33748101092
-
MUC1 cytoplasmic tail: A potential therapeutic target for ovarian carcinoma
-
DOI 10.1586/14737140.6.8.1261
-
Hu X. F., Yang E., Li J., Xing P. X., MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma Expert Review of Anticancer Therapy 2006 6 8 1261 1271 (Pubitemid 44304694)
-
(2006)
Expert Review of Anticancer Therapy
, vol.6
, Issue.8
, pp. 1261-1271
-
-
Hu, X.F.1
Yang, E.2
Li, J.3
Xing, P.X.4
-
84
-
-
0035370711
-
The importance of MUC1 cellular localization in patients with breast carcinoma: An immunohistologic study of 71 patients and review of the literature
-
DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A
-
Rahn J. J., Dabbagh L., Pasdar M., Hugh J. C., The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature Cancer 2001 91 11 1973 1982 (Pubitemid 32476360)
-
(2001)
Cancer
, vol.91
, Issue.11
, pp. 1973-1982
-
-
Rahn, J.J.1
Dabbagh, L.2
Pasdar, M.3
Hugh, J.C.4
-
85
-
-
0030070154
-
The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells
-
DOI 10.1074/jbc.271.4.2332
-
Pemberton L. F., Rughetti A., Taylor-Papadimitriou J., Gendler S. J., The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells Journal of Biological Chemistry 1996 271 4 2332 2340 (Pubitemid 26047827)
-
(1996)
Journal of Biological Chemistry
, vol.271
, Issue.4
, pp. 2332-2340
-
-
Pemberton, L.F.1
Rughetti, A.2
Taylor-Papadimitriou, J.3
Gendler, S.J.4
-
86
-
-
0027195386
-
Human B-cell immune response to the polymorphic epithelial mucin
-
Rughetti A., Turchi V., Ghetti C. A., Scambia G., Panici P. B., Roncucci G., Mancuso S., Frati L., Nuti M., Human B-cell immune response to the polymorphic epithelial mucin Cancer Research 1993 52 11 2457 2459 (Pubitemid 23168003)
-
(1993)
Cancer Research
, vol.53
, Issue.11
, pp. 2457-2459
-
-
Rughetti, A.1
Turchi, V.2
Ghetti, C.A.3
Scambia, G.4
Panici, P.B.5
Roncucci, G.6
Mancuso, S.7
Frati, L.8
Nuti, M.9
-
88
-
-
0025674108
-
Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer
-
Stewart J. S., Hird V., Snook D., Dhokia B., Sivolapenko G., Hooker G., Papadimitriou J. T., Rowlinson G., Sullivan M., Lambert H. E., Coulter C., Mason W. P., Soutter W. P., Epenetos A. A., Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer Journal of Clinical Oncology 1990 8 12 1941 1950
-
(1990)
Journal of Clinical Oncology
, vol.8
, Issue.12
, pp. 1941-1950
-
-
Stewart, J.S.1
Hird, V.2
Snook, D.3
Dhokia, B.4
Sivolapenko, G.5
Hooker, G.6
Papadimitriou, J.T.7
Rowlinson, G.8
Sullivan, M.9
Lambert, H.E.10
Coulter, C.11
Mason, W.P.12
Soutter, W.P.13
Epenetos, A.A.14
-
89
-
-
0031985010
-
Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: A matched analysis
-
Maraveyas A., Mason P., Lambert H. E., Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis Oncology Reports 2001 5 1 223 226
-
(2001)
Oncology Reports
, vol.5
, Issue.1
, pp. 223-226
-
-
Maraveyas, A.1
Mason, P.2
Lambert, H.E.3
-
90
-
-
0034004410
-
Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy
-
DOI 10.1046/j.1525-1438.2000.99510.x
-
Epenetos A. A., Hird V., Lambert H., Mason P., Coulter C., Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy International Journal of Gynecological Cancer 2000 10 1 44 46 (Pubitemid 30220628)
-
(2000)
International Journal of Gynecological Cancer
, vol.10
, Issue.SUPPL. 1
, pp. 44-46
-
-
Epenetos, A.A.1
Hird, V.2
Lambert, H.3
Mason, P.4
Coulter, C.5
-
91
-
-
4344712401
-
A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer
-
Nicholson S., Bomphray C. C., Thomas H., McIndoe A., Barton D., Gore M., George A. J. T., A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer Cancer Immunology, Immunotherapy 2004 53 9 809 816 (Pubitemid 39149908)
-
(2004)
Cancer Immunology, Immunotherapy
, vol.53
, Issue.9
, pp. 809-816
-
-
Nicholson, S.1
Bomphray, C.C.2
Thomas, H.3
McIndoe, A.4
Barton, D.5
Gore, M.6
George, A.J.T.7
-
92
-
-
33644834874
-
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission
-
DOI 10.1200/JCO.2005.02.5973
-
Verheijen R. H., Massuger L. F., Benigno B. B., Epenetos A. A., Lopes A., Soper J. T., Markowska J., Vyzula R., Jobling T., Stamp G., Spiegel G., Thurston D., Falke T., Lambert J., Seiden M. V., Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission Journal of Clinical Oncology 2006 24 4 571 578 (Pubitemid 46655592)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.4
, pp. 571-578
-
-
Verheijen, R.H.1
Massuger, L.F.2
Benigno, B.B.3
Epenetos, A.A.4
Lopes, A.5
Soper, J.T.6
Markowska, J.7
Vyzula, R.8
Jobling, T.9
Stamp, G.10
Spiegel, G.11
Thurston, D.12
Falke, T.13
Lambert, J.14
Seiden, M.V.15
-
93
-
-
48149110374
-
The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)
-
Oei A. L., Sweep F. C., Thomas C. M., Boerman O. C., Massuger L. F. A. G., The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review) International Journal of Oncology 2008 32 6 1145 1157
-
(2008)
International Journal of Oncology
, vol.32
, Issue.6
, pp. 1145-1157
-
-
Oei, A.L.1
Sweep, F.C.2
Thomas, C.M.3
Boerman, O.C.4
Massuger, L.F.A.G.5
-
94
-
-
51949104317
-
Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer
-
Oei A. L., Moreno M., Verheijen R. H., Sweep F. C. G. J., Thomas C. M. G., Massuger L. F. A. G., von Mensdorff-Pouilly S., Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer International Journal of Cancer 2008 123 8 1848 1853
-
(2008)
International Journal of Cancer
, vol.123
, Issue.8
, pp. 1848-1853
-
-
Oei, A.L.1
Moreno, M.2
Verheijen, R.H.3
Sweep, F.C.G.J.4
Thomas, C.M.G.5
Massuger, L.F.A.G.6
Von Mensdorff-Pouilly, S.7
-
95
-
-
84855578032
-
-
http://www.antisoma.com/
-
-
-
-
96
-
-
51149116051
-
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
-
Hodi F. S., Oble D. A., Drappatz J., Velazquez E. F., Ramaiya N., Ramakrishna N., Day A. L., Kruse A., Rae S. M., Hoos A., Mihm M., CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS Nature Clinical Practice Oncology 2008 5 9 557 561
-
(2008)
Nature Clinical Practice Oncology
, vol.5
, Issue.9
, pp. 557-561
-
-
Hodi, F.S.1
Oble, D.A.2
Drappatz, J.3
Velazquez, E.F.4
Ramaiya, N.5
Ramakrishna, N.6
Day, A.L.7
Kruse, A.8
Rae, S.M.9
Hoos, A.10
Mihm, M.11
-
97
-
-
61449097778
-
Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer
-
Kuemmel S., Thomas A., Landt S., Fuger A., Schmid P., Kriner M., Blohmer J. U., Sehouli J., Schaller G., Lichtenegger W., Kninger A., Fuchs I., Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer Anticancer Research 2009 29 2 641 645
-
(2009)
Anticancer Research
, vol.29
, Issue.2
, pp. 641-645
-
-
Kuemmel, S.1
Thomas, A.2
Landt, S.3
Fuger, A.4
Schmid, P.5
Kriner, M.6
Blohmer, J.U.7
Sehouli, J.8
Schaller, G.9
Lichtenegger, W.10
Kninger, A.11
Fuchs, I.12
-
98
-
-
60449083456
-
Markers of angiogenesis in high-risk, early-stage cervical cancer: A gynecologic oncology group study
-
Randall L. M., Monk B. J., Darcy K. M., Tian C., Burger R. A., Liao S. -Y., Peters W. A., Stock R. J., Fruehauf J. P., Markers of angiogenesis in high-risk, early-stage cervical cancer: a gynecologic oncology group study Gynecologic Oncology 2009 112 3 583 589
-
(2009)
Gynecologic Oncology
, vol.112
, Issue.3
, pp. 583-589
-
-
Randall, L.M.1
Monk, B.J.2
Darcy, K.M.3
Tian, C.4
Burger, R.A.5
Liao, S.-Y.6
Peters, W.A.7
Stock, R.J.8
Fruehauf, J.P.9
-
99
-
-
0033790637
-
Vascular endothelial growth factor and prognosis of cervical carcinoma
-
Cheng W. F., Chen C. A., Lee C. N., Wei L. H., Hsieh F. J., Hsieh C. Y., Vascular endothelial growth factor and prognosis of cervical carcinoma Obstetrics and Gynecology 2000 96 5 721 726
-
(2000)
Obstetrics and Gynecology
, vol.96
, Issue.5
, pp. 721-726
-
-
Cheng, W.F.1
Chen, C.A.2
Lee, C.N.3
Wei, L.H.4
Hsieh, F.J.5
Hsieh, C.Y.6
-
100
-
-
0033899157
-
Vascular endothelial growth factor (VEGF) expression is a prognostic faster for radiotherapy outcome in advanced carcinoma of the cervix
-
Loncaster J. A., Cooper R. A., Logue J. P., Davidson S. E., Hunter R. D., West C. M. L., Vascular endothelial growth factor (VEGF) expression is a prognostic faster for radiotherapy outcome in advanced carcinoma of the cervix British Journal of Cancer 2000 83 5 620 625 (Pubitemid 30636303)
-
(2000)
British Journal of Cancer
, vol.83
, Issue.5
, pp. 620-625
-
-
Loncaster, J.A.1
Cooper, R.A.2
Logue, J.P.3
Davidson, S.E.4
Hunter, R.D.5
West, C.M.L.6
-
101
-
-
61549141361
-
Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A gynecologic oncology group study
-
Monk B. J., Sill M. W., Burger R. A., Gray H. J., Buekers T. E., Roman L. D., Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study Journal of Clinical Oncology 2009 27 7 1069 1074
-
(2009)
Journal of Clinical Oncology
, vol.27
, Issue.7
, pp. 1069-1074
-
-
Monk, B.J.1
Sill, M.W.2
Burger, R.A.3
Gray, H.J.4
Buekers, T.E.5
Roman, L.D.6
-
102
-
-
33745308428
-
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis
-
DOI 10.1002/cncr.21969
-
Wright J. D., Hagemann A., Rader J. S., Viviano D., Gibb R. K., Norris L., Mutch D. G., Powell M. A., Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis Cancer 2006 107 1 83 89 (Pubitemid 43939034)
-
(2006)
Cancer
, vol.107
, Issue.1
, pp. 83-89
-
-
Wright, J.D.1
Hagemann, A.2
Rader, J.S.3
Viviano, D.4
Gibb, R.K.5
Norris, L.6
Mutch, D.G.7
Powell, M.A.8
-
103
-
-
84855583549
-
-
(ID protocol number: NCT00803062)
-
http://www.cancer.gov/ (ID protocol number: NCT00803062)
-
-
-
-
104
-
-
80052560749
-
Is there a real standard for stage Iva cervical cancer?
-
Bellati F., Gasparri M. L., Panici P. B., Is there a real standard for stage Iva cervical cancer? Gynecologic Oncology 2011 123 1 174 175
-
(2011)
Gynecologic Oncology
, vol.123
, Issue.1
, pp. 174-175
-
-
Bellati, F.1
Gasparri, M.L.2
Panici, P.B.3
-
105
-
-
34748875485
-
An update in neoadjuvant chemotherapy in cervical cancer
-
Panici P. B., Bellati F., Pastore M., Manci N., Musella A., Pauselli S., Angelucci M., Muzii L., Angioli R., An update in neoadjuvant chemotherapy in cervical cancer Gynecologic Oncology 2007 107 supplement 1 S20 S22
-
(2007)
Gynecologic Oncology
, vol.107
, Issue.SUPPL. 1
-
-
Panici, P.B.1
Bellati, F.2
Pastore, M.3
Manci, N.4
Musella, A.5
Pauselli, S.6
Angelucci, M.7
Muzii, L.8
Angioli, R.9
-
106
-
-
34548559534
-
Neoadjuvant chemotherapy followed by radical surgery in patients affected by FIGO stage IVA cervical cancer
-
DOI 10.1245/s10434-007-9408-6
-
Panici P. B., Bellati F., Manci N., Pernice M., Plotti F., di Donato V., Calcagno M., Zullo M. A., Muzii L., Angioli R., Neoadjuvant chemotherapy followed by radical surgery in patients affected by FIGO stage IVA cervical cancer Annals of Surgical Oncology 2007 14 9 2643 2648 (Pubitemid 47389564)
-
(2007)
Annals of Surgical Oncology
, vol.14
, Issue.9
, pp. 2643-2648
-
-
Benedetti Panici, P.1
Bellati, F.2
Manci, N.3
Pernice, M.4
Plotti, F.5
Di Donato, V.6
Calcagno, M.7
Zullo, M.A.8
Muzii, L.9
Angioli, R.10
-
107
-
-
0027518792
-
Prognostic value of epidermal growth factor receptor expression in cervical carcinoma
-
Hale R. J., Buckley C. H., Gullick W. J., Fox H., Williams J., Wilcox F. L., Prognostic value of epidermal growth factor receptor expression in cervical carcinoma Journal of Clinical Pathology 1993 46 2 149 153 (Pubitemid 23076346)
-
(1993)
Journal of Clinical Pathology
, vol.46
, Issue.2
, pp. 149-153
-
-
Hale, R.J.1
Buckley, C.H.2
Gullick, W.J.3
Fox, H.4
Williams, J.5
Wilcox, F.L.6
-
108
-
-
0033042754
-
Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis
-
Kersemaekers A. M., Fleuren G. J., Kenter G. G., van den Broek L. J. C. M., Uljee S. M., Hermans J., van de Vijver M. J., Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis Clinical Cancer Research 1999 5 3 577 586 (Pubitemid 29131967)
-
(1999)
Clinical Cancer Research
, vol.5
, Issue.3
, pp. 577-586
-
-
Kersemaekers, A.-M.F.1
Fleuren, G.J.2
Kenter, G.G.3
Van Den Broek, L.J.C.M.4
Uljee, S.M.5
Hermans, J.6
Van De Vijver, M.J.7
-
109
-
-
12144290754
-
Synchronous Coexpression of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in Carcinomas of the Uterine Cervix: A Potential Predictor of Poor Survival
-
DOI 10.1158/1078-0432.CCR-0497-03
-
Kim G. E., Kim Y. B., Cho N. H., Chung H. C., Pyo H. R., Lee J. D., Park T. K., Koom W. S., Chun M., Suh C. O., Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival Clinical Cancer Research 2004 10 4 1366 1374 (Pubitemid 38365230)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.4
, pp. 1366-1374
-
-
Kim, G.E.1
Kim, Y.B.2
Cho, N.H.3
Chung, H.-C.4
Pyo, H.R.5
Lee, J.D.6
Park, T.K.7
Koom, W.S.8
Chun, M.9
Suh, C.O.10
-
110
-
-
0034485637
-
Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma
-
Oh M. J., Choi J. H., Kim I. H., Lee Y. H., Huh J. Y., Park Y. K., Lee K. W., Chough S. Y., Joo K. S., Ku B. S., Saw H. S., Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma Clinical Cancer Research 2000 6 12 4760 4763
-
(2000)
Clinical Cancer Research
, vol.6
, Issue.12
, pp. 4760-4763
-
-
Oh, M.J.1
Choi, J.H.2
Kim, I.H.3
Lee, Y.H.4
Huh, J.Y.5
Park, Y.K.6
Lee, K.W.7
Chough, S.Y.8
Joo, K.S.9
Ku, B.S.10
Saw, H.S.11
-
111
-
-
0024599422
-
Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix
-
DOI 10.1016/0090-8258(89)90540-4
-
Pfeiffer D., Stellwag B., Pfeiffer A., Borlinghaus P., Mjeier W., Scheidel P., Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix Gynecologic Oncology 1989 33 2 146 150 (Pubitemid 19112903)
-
(1989)
Gynecologic Oncology
, vol.33
, Issue.2
, pp. 146-150
-
-
Pfeiffer, D.1
Stellwag, B.2
Pfeiffer, A.3
Borlinghaus, P.4
Mjeier, W.5
Scheidel, P.6
-
112
-
-
34548124985
-
Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
-
DOI 10.1016/j.ygyno.2007.04.028, PII S0090825807003022
-
Bellone J., Norton L., Masui H., Romani C., Bandiera E., Tognon G., Roman J. J., Burnett A. F., Pecorelli S., Santin A. D., Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease Gynecologic Oncology 2007 106 3 513 520 (Pubitemid 47302461)
-
(2007)
Gynecologic Oncology
, vol.106
, Issue.3
, pp. 513-520
-
-
Bellone, S.1
Frera, G.2
Landolfi, G.3
Romani, C.4
Bandiera, E.5
Tognon, G.6
Roman, J.J.7
Burnett, A.F.8
Pecorelli, S.9
Santin, A.D.10
-
113
-
-
20144381957
-
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
-
DOI 10.1200/JCO.2005.08.037
-
Chung K. Y., Shia J., Kemeny N. E., Shah M., Schwartz G. K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., Klimstra D. S., Fridman D., Kelsen D. P., Saltz L. B., Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry Journal of Clinical Oncology 2005 23 9 1803 1810 (Pubitemid 46211358)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.9
, pp. 1803-1810
-
-
Chung, K.Y.1
Shia, J.2
Kemeny, N.E.3
Shah, M.4
Schwartz, G.K.5
Tse, A.6
Hamilton, A.7
Pan, D.8
Schrag, D.9
Schwartz, L.10
Klimstra, D.S.11
Fridman, D.12
Kelsen, D.P.13
Saltz, L.B.14
-
114
-
-
34548124985
-
Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
-
DOI 10.1016/j.ygyno.2007.04.028, PII S0090825807003022
-
Bellone S., Frera G., Landolfi G., Romani C., Bandiera E., Tognon G., Roman J. J., Burnett A. F., Pecorelli S., Santin A. D., Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease Gynecologic Oncology 2007 106 3 513 520 (Pubitemid 47302461)
-
(2007)
Gynecologic Oncology
, vol.106
, Issue.3
, pp. 513-520
-
-
Bellone, S.1
Frera, G.2
Landolfi, G.3
Romani, C.4
Bandiera, E.5
Tognon, G.6
Roman, J.J.7
Burnett, A.F.8
Pecorelli, S.9
Santin, A.D.10
-
115
-
-
70249143558
-
Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: Mechanisms of sensitisation of cervical cancer cells
-
Meira D. D., de Almeida V. H., Moror J. S., Nbrega I., Bardella L., Silva R. L. A., Albano R. M., Ferreira C. G., Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells British Journal of Cancer 2009 101 5 782 791
-
(2009)
British Journal of Cancer
, vol.101
, Issue.5
, pp. 782-791
-
-
Meira, D.D.1
De Almeida, V.H.2
Moror, J.S.3
Nbrega, I.4
Bardella, L.5
Silva, R.L.A.6
Albano, R.M.7
Ferreira, C.G.8
-
116
-
-
80051551247
-
Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A gynecologic oncology group study
-
Santin A. D., Sill M. W., McMeekin D. S., Leitao M. M., Brown J., Sutton G. P., van Le L., Griffin P., Boardman C. H., Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a gynecologic oncology group study Gynecologic Oncology 2011 122 3 495 500
-
(2011)
Gynecologic Oncology
, vol.122
, Issue.3
, pp. 495-500
-
-
Santin, A.D.1
Sill, M.W.2
McMeekin, D.S.3
Leitao, M.M.4
Brown, J.5
Sutton, G.P.6
Van Le, L.7
Griffin, P.8
Boardman, C.H.9
-
117
-
-
62749156047
-
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial
-
Kurtz J. E., Hardy-Bessard A. C., Deslandres M., Lavau-Denes S., Largillier R., Roemer-Becuwe C., Weber B., Guillemet C., Paraiso D., Pujade-Lauraine E., Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial Gynecologic Oncology 2009 113 1 16 20
-
(2009)
Gynecologic Oncology
, vol.113
, Issue.1
, pp. 16-20
-
-
Kurtz, J.E.1
Hardy-Bessard, A.C.2
Deslandres, M.3
Lavau-Denes, S.4
Largillier, R.5
Roemer-Becuwe, C.6
Weber, B.7
Guillemet, C.8
Paraiso, D.9
Pujade-Lauraine, E.10
-
118
-
-
78751582338
-
Cetuximab monotherapy in advanced cervical cancer: A retrospective study with five patients
-
Hertlein L., Lenhard M., Kirschenhofer A., Kahlert S., Mayr D., Burges A., Friese K., Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients Archives of Gynecology and Obstetrics 2011 283 1 109 113
-
(2011)
Archives of Gynecology and Obstetrics
, vol.283
, Issue.1
, pp. 109-113
-
-
Hertlein, L.1
Lenhard, M.2
Kirschenhofer, A.3
Kahlert, S.4
Mayr, D.5
Burges, A.6
Friese, K.7
-
119
-
-
79955481029
-
Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A gynecologic oncology group study
-
Farley J., Sill M. W., Birrer M., Walker J., Schilder R. J., Thigpen J. T., Coleman R. L., Miller B. E., Rose P. G., Lankes H. A., Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a gynecologic oncology group study Gynecologic Oncology 2011 121 2 303 308
-
(2011)
Gynecologic Oncology
, vol.121
, Issue.2
, pp. 303-308
-
-
Farley, J.1
Sill, M.W.2
Birrer, M.3
Walker, J.4
Schilder, R.J.5
Thigpen, J.T.6
Coleman, R.L.7
Miller, B.E.8
Rose, P.G.9
Lankes, H.A.10
-
120
-
-
68749085025
-
A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: A gynecologic oncology group (GOG) studyASCO
-
Aghajanian C., Sill M. W., Darcy K., A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a gynecologic oncology group (GOG) studyASCO Journal of Clinical Oncology 2009 27 15s
-
(2009)
Journal of Clinical Oncology
, vol.27
-
-
Aghajanian, C.1
Sill, M.W.2
Darcy, K.3
-
121
-
-
35348985425
-
Bevacizumab therapy in patients with recurrent uterine neoplasms
-
Wright J. D., Powell M. A., Rader J. S., Mutch D. G., Gibb R. K., Bevacizumab therapy in patients with recurrent uterine neoplasms Anticancer Research 2007 27 5 3525 3528 (Pubitemid 47607497)
-
(2007)
Anticancer Research
, vol.27
, Issue.B5
, pp. 3525-3528
-
-
Wright, J.D.1
Powell, M.A.2
Rader, J.S.3
Mutch, D.G.4
Gibb, R.K.5
-
122
-
-
70349878651
-
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial
-
Katsumata N., Yasuda M., Takahashi F., Isonishi S., Jobo T., Aoki D., Tsuda H., Sugiyama T., Kodama S., Kimura E., Ochiai K., Noda K., Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial The Lancet 2009 374 9698 1331 1338
-
(2009)
The Lancet
, vol.374
, Issue.9698
, pp. 1331-1338
-
-
Katsumata, N.1
Yasuda, M.2
Takahashi, F.3
Isonishi, S.4
Jobo, T.5
Aoki, D.6
Tsuda, H.7
Sugiyama, T.8
Kodama, S.9
Kimura, E.10
Ochiai, K.11
Noda, K.12
-
123
-
-
79955477996
-
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
-
O'Malley D. M., Richardson D. L., Rheaume P. S., Salani R., Eisenhauer E. L., McCann G. A., Fowler J. M., Copeland L. J., Cohn D. E., Backes F. J., Addition of bevacizumab to weekly paclitaxel significantly improves
-
(2011)
Gynecologic Oncology
, vol.121
, Issue.2
, pp. 269-272
-
-
O'Malley, D.M.1
Richardson, D.L.2
Rheaume, P.S.3
Salani, R.4
Eisenhauer, E.L.5
McCann, G.A.6
Fowler, J.M.7
Copeland, L.J.8
Cohn, D.E.9
Backes, F.J.10
-
124
-
-
83055173012
-
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
-
In press
-
Markman M., Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecologic Oncology. In press
-
Gynecologic Oncology
-
-
Markman, M.1
-
125
-
-
8344227715
-
Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?
-
DOI 10.1097/00001813-200410000-00007
-
Lau D., Guo L., Gandara D., Young L. J. T., Xue L., Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anti-Cancer Drugs 2004 15 9 871 875 (Pubitemid 39482927)
-
(2004)
Anti-Cancer Drugs
, vol.15
, Issue.9
, pp. 871-875
-
-
Lau, D.1
Guo, L.2
Gandara, D.3
Young, L.J.T.4
Xue, L.5
-
126
-
-
53249111894
-
Limited clinical benefit from trastuzumab in recurrent endometrial cancer: Two case reports
-
Vandenput I., Bempt I. V., Leunen K., Neven P., Berteloot P., Moerman P., Vergote I., Amant F., Limited clinical benefit from trastuzumab in recurrent endometrial cancer: two case reports Gynecologic and Obstetric Investigation 2009 67 1 46 48
-
(2009)
Gynecologic and Obstetric Investigation
, vol.67
, Issue.1
, pp. 46-48
-
-
Vandenput, I.1
Bempt, I.V.2
Leunen, K.3
Neven, P.4
Berteloot, P.5
Moerman, P.6
Vergote, I.7
Amant, F.8
|